Business Description
PT Kalbe Farma Tbk
NAICS : 325412
ISIN : US69368A1088
Share Class Description:
PTKFY: ADRDescription
Kalbe Farma is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company primarily operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.49 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.15 | |||||
| Interest Coverage | 43.7 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 13.31 | |||||
| Beneish M-Score | -2.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | 0.3 | |||||
| 3-Year EPS without NRI Growth Rate | 1.6 | |||||
| 3-Year FCF Growth Rate | -17.4 | |||||
| 3-Year Book Growth Rate | 7.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.38 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | 0.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.91 | |||||
| Quick Ratio | 2.81 | |||||
| Cash Ratio | 1.05 | |||||
| Days Inventory | 141.3 | |||||
| Days Sales Outstanding | 59.36 | |||||
| Days Payable | 39.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.65 | |||||
| 3-Year Dividend Growth Rate | 13.5 | |||||
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 2.4 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.83 | |||||
| Operating Margin % | 11.91 | |||||
| Net Margin % | 9.09 | |||||
| FCF Margin % | 5.61 | |||||
| ROE % | 13.33 | |||||
| ROA % | 10.09 | |||||
| ROIC % | 13.19 | |||||
| ROC (Joel Greenblatt) % | 20.45 | |||||
| ROCE % | 15.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.01 | |||||
| Forward PE Ratio | 19.72 | |||||
| PE Ratio without NRI | 24.13 | |||||
| Shiller PE Ratio | 22.65 | |||||
| Price-to-Owner-Earnings | 31.24 | |||||
| PEG Ratio | 5.25 | |||||
| PS Ratio | 2.18 | |||||
| PB Ratio | 3.09 | |||||
| Price-to-Tangible-Book | 3.37 | |||||
| Price-to-Free-Cash-Flow | 38.36 | |||||
| Price-to-Operating-Cash-Flow | 22.82 | |||||
| EV-to-EBIT | 17.18 | |||||
| EV-to-Forward-EBIT | 14.85 | |||||
| EV-to-EBITDA | 15.75 | |||||
| EV-to-Forward-EBITDA | 14.49 | |||||
| EV-to-Revenue | 2.08 | |||||
| EV-to-Forward-Revenue | 2.45 | |||||
| EV-to-FCF | 36.66 | |||||
| Price-to-Projected-FCF | 1.95 | |||||
| Price-to-DCF (Earnings Based) | 3.24 | |||||
| Price-to-DCF (FCF Based) | 5.22 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4 | |||||
| Price-to-Graham-Number | 1.9 | |||||
| Price-to-Net-Current-Asset-Value | 6.44 | |||||
| Earnings Yield (Greenblatt) % | 5.82 | |||||
| FCF Yield % | 2.61 | |||||
| Forward Rate of Return (Yacktman) % | 8.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PTKFY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PT Kalbe Farma Tbk Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,996.075 | ||
| EPS (TTM) ($) | 0.782 | ||
| Beta | -0.21 | ||
| Volatility % | 2.21 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 29.1 | ||
| 12-1 Month Momentum % | 0.45 | ||
| 52-Week Range ($) | 28.97 - 29.1 | ||
| Shares Outstanding (Mil) | 231.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PT Kalbe Farma Tbk Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PT Kalbe Farma Tbk Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
PT Kalbe Farma Tbk Frequently Asked Questions
What is PT Kalbe Farma Tbk(PTKFY)'s stock price today?
The current price of PTKFY is $29.10. The 52 week high of PTKFY is $29.10 and 52 week low is $28.97.
When is next earnings date of PT Kalbe Farma Tbk(PTKFY)?
The next earnings date of PT Kalbe Farma Tbk(PTKFY) is .
Does PT Kalbe Farma Tbk(PTKFY) pay dividends? If so, how much?
PT Kalbe Farma Tbk(PTKFY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers